MEDIFAST INC (MED) Fundamental Analysis & Valuation

NYSE:MED • US58470H1014

Current stock price

10.52 USD
+0.16 (+1.54%)
At close:
10.52 USD
0 (0%)
After Hours:

This MED fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. MED Profitability Analysis

1.1 Basic Checks

  • In the past year MED has reported negative net income.
  • In the past year MED had a positive cash flow from operations.
  • MED had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years MED had a positive operating cash flow.
MED Yearly Net Income VS EBIT VS OCF VS FCFMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

1.2 Ratios

  • MED has a Return On Assets of -7.53%. This is in the lower half of the industry: MED underperforms 70.27% of its industry peers.
  • MED's Return On Equity of -9.39% is in line compared to the rest of the industry. MED outperforms 48.65% of its industry peers.
Industry RankSector Rank
ROA -7.53%
ROE -9.39%
ROIC N/A
ROA(3y)8.43%
ROA(5y)22.37%
ROE(3y)13.65%
ROE(5y)42.92%
ROIC(3y)N/A
ROIC(5y)N/A
MED Yearly ROA, ROE, ROICMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

1.3 Margins

  • With a decent Gross Margin value of 71.33%, MED is doing good in the industry, outperforming 70.27% of the companies in the same industry.
  • MED's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MED so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y-0.9%
MED Yearly Profit, Operating, Gross MarginsMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. MED Health Analysis

2.1 Basic Checks

  • MED does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MED has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MED has been reduced compared to 5 years ago.
  • MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MED Yearly Shares OutstandingMED Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
MED Yearly Total Debt VS Total AssetsMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 4.41 indicates that MED is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of MED (4.41) is better than 83.78% of its industry peers.
  • MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.41
ROIC/WACCN/A
WACC8.99%
MED Yearly LT Debt VS Equity VS FCFMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.3 Liquidity

  • MED has a Current Ratio of 4.69. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
  • MED has a better Current ratio (4.69) than 86.49% of its industry peers.
  • A Quick Ratio of 4.22 indicates that MED has no problem at all paying its short term obligations.
  • The Quick ratio of MED (4.22) is better than 91.89% of its industry peers.
Industry RankSector Rank
Current Ratio 4.69
Quick Ratio 4.22
MED Yearly Current Assets VS Current LiabilitesMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MED Growth Analysis

3.1 Past

  • MED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -186.21%.
  • Looking at the last year, MED shows a very negative growth in Revenue. The Revenue has decreased by -35.96% in the last year.
  • The Revenue for MED have been decreasing by -16.22% on average. This is quite bad
EPS 1Y (TTM)-186.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1750%
Revenue 1Y (TTM)-35.96%
Revenue growth 3Y-37.74%
Revenue growth 5Y-16.22%
Sales Q2Q%-36.9%

3.2 Future

  • Based on estimates for the next years, MED will show a very negative growth in Earnings Per Share. The EPS will decrease by -26.21% on average per year.
  • MED is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -19.23% yearly.
EPS Next Y-14.27%
EPS Next 2Y-26.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-27.82%
Revenue Next 2Y-19.23%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
MED Yearly Revenue VS EstimatesMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
MED Yearly EPS VS EstimatesMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. MED Valuation Analysis

4.1 Price/Earnings Ratio

  • MED reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MED. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MED Price Earnings VS Forward Price EarningsMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • MED's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 92.57
EV/EBITDA N/A
MED Per share dataMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • A cheap valuation may be justified as MED's earnings are expected to decrease with -26.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.21%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. MED Dividend Analysis

5.1 Amount

  • MED has a Yearly Dividend Yield of 9.97%, which is a nice return.
  • MED's Dividend Yield is rather good when compared to the industry average which is at 1.76. MED pays more dividend than 97.30% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, MED pays a better dividend.
Industry RankSector Rank
Dividend Yield 9.97%

5.2 History

  • The dividend of MED decreases each year by -66.94%.
  • MED has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-66.94%
Div Incr Years0
Div Non Decr Years0
MED Yearly Dividends per shareMED Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2 4 6

5.3 Sustainability

  • The earnings of MED are negative and hence is the payout ratio. MED will probably not be able to sustain this dividend level.
  • MED's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
DP-1.04%
EPS Next 2Y-26.21%
EPS Next 3YN/A
MED Yearly Income VS Free CF VS DividendMED Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

MED Fundamentals: All Metrics, Ratios and Statistics

MEDIFAST INC

NYSE:MED (4/6/2026, 8:04:00 PM)

After market: 10.52 0 (0%)

10.52

+0.16 (+1.54%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)02-17
Earnings (Next)04-27
Inst Owners74.16%
Inst Owner Change0%
Ins Owners3.18%
Ins Owner Change4.25%
Market Cap115.61M
Revenue(TTM)385.79M
Net Income(TTM)-18.67M
Analysts46.67
Price Target12.24 (16.35%)
Short Float %19.16%
Short Ratio7.67
Dividend
Industry RankSector Rank
Dividend Yield 9.97%
Yearly Dividend0.02
Dividend Growth(5Y)-66.94%
DP-1.04%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-26.27%
Min EPS beat(2)-99.23%
Max EPS beat(2)46.69%
EPS beat(4)3
Avg EPS beat(4)51.53%
Min EPS beat(4)-99.23%
Max EPS beat(4)199.01%
EPS beat(8)6
Avg EPS beat(8)88.81%
EPS beat(12)9
Avg EPS beat(12)75.52%
EPS beat(16)12
Avg EPS beat(16)64.12%
Revenue beat(2)2
Avg Revenue beat(2)3%
Min Revenue beat(2)0.75%
Max Revenue beat(2)5.26%
Revenue beat(4)4
Avg Revenue beat(4)4.71%
Min Revenue beat(4)0.75%
Max Revenue beat(4)8.75%
Revenue beat(8)7
Avg Revenue beat(8)2.97%
Revenue beat(12)11
Avg Revenue beat(12)3.64%
Revenue beat(16)15
Avg Revenue beat(16)3.64%
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-44.44%
EPS NY rev (1m)0%
EPS NY rev (3m)-1423.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-22.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF 92.57
P/OCF 16.85
P/B 0.58
P/tB 0.58
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)0.11
FCFY1.08%
OCF(TTM)0.62
OCFY5.94%
SpS35.1
BVpS18.1
TBVpS18.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.53%
ROE -9.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.33%
FCFM 0.32%
ROA(3y)8.43%
ROA(5y)22.37%
ROE(3y)13.65%
ROE(5y)42.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y-0.9%
F-Score4
Asset Turnover1.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 39.42%
Cap/Sales 1.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.69
Quick Ratio 4.22
Altman-Z 4.41
F-Score4
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)49.18%
Cap/Depr(5y)160.46%
Cap/Sales(3y)1.1%
Cap/Sales(5y)1.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-186.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1750%
EPS Next Y-14.27%
EPS Next 2Y-26.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-35.96%
Revenue growth 3Y-37.74%
Revenue growth 5Y-16.22%
Sales Q2Q%-36.9%
Revenue Next Year-27.82%
Revenue Next 2Y-19.23%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-167.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.66%
FCF growth 3Y-80.85%
FCF growth 5Y-61.05%
OCF growth 1Y-71.96%
OCF growth 3Y-67.21%
OCF growth 5Y-45.69%

MEDIFAST INC / MED Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MED.


Can you provide the valuation status for MEDIFAST INC?

ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.


How profitable is MEDIFAST INC (MED) stock?

MEDIFAST INC (MED) has a profitability rating of 3 / 10.


What is the earnings growth outlook for MEDIFAST INC?

The Earnings per Share (EPS) of MEDIFAST INC (MED) is expected to decline by -14.27% in the next year.


Is the dividend of MEDIFAST INC sustainable?

The dividend rating of MEDIFAST INC (MED) is 5 / 10 and the dividend payout ratio is -1.04%.